Arrowstreet Capital, Limited Partnership Summit Therapeutics Inc. Transaction History
Arrowstreet Capital, Limited Partnership
- $114 Billion
- Q2 2024
A detailed history of Arrowstreet Capital, Limited Partnership transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Arrowstreet Capital, Limited Partnership holds 141,680 shares of SMMT stock, worth $3.08 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
141,680Holding current value
$3.08 Million% of portfolio
0.0%Shares
4 transactions
Others Institutions Holding SMMT
# of Institutions
158Shares Held
67.1MCall Options Held
1.05MPut Options Held
1.07M-
Baker Bros. Advisors LP New York, NY23.2MShares$506 Million2.41% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.82MShares$192 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.9MShares$172 Million0.0% of portfolio
-
State Street Corp Boston, MA4.12MShares$89.8 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA3.1MShares$67.5 Million0.01% of portfolio
About Summit Therapeutics Inc.
- Ticker SMMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 201,215,008
- Market Cap $4.38B
- Description
- Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...